An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010).

PI: Giulia Bianchi

A Phase 3, randomized, 1:1, open-label study using the investigational drug MK-2870 in patients with unresectable HR+/HER2- locally advanced or metastatic breast cancer. The study design includes three arms (ARM A: MK-2870, ARM B: MK-2870 + Pembrolizumab, ARM C: investigator's choice of standard therapy). Inclusion criteria are centralized confirmation of HR+/HER2- histology and disease recurrence with/after CDK4/6i (early or metastatic).